Home > Insider Trading > Filing (0001140361-14-026846)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1297000	Denise Pollard-Knight	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-06-25	3,252	$23.56	2,054,994	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote

Footnotes

The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
Sales prices range from $23.55 to $23.66 per share, inclusive.
The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.